UBS analyst upgraded Jazz Pharmaceuticals two notches, a rare large move. The stock has seen strong momentum, rising 18% in the past month and 39% in three months. Morgan Stanley raised its price target to $245 with an Overweight rating. Raymond James also increased its price target. The stock is trading at $239.83 with a one-year return of 121.9%.